SEARCH

SEARCH BY CITATION

References

  • Affolter H, Hertel C, Jaeggi K, Portenier M, Staehelin M (1985). (-)-S-[3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists. Proc Natl Acad Sci USA 82: 925929.
  • Anderson GP, Linden A, Rabe KF (1994). Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7: 569578.
  • Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D et al. (2006). In vitro and in vivo pharmacological characterization of 5-[(R)2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317: 762770.
  • Beattie D, Bradley M, Brearley A, Charlton SJ, Cuenoud BM, Fairhurst RA et al. (2010). A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators. Bioorg Med Chem Lett 20: 53025307.
  • Beeh KM, Beier J (2010). The short, the long and the ‘ultra-long’: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 27: 150159.
  • Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (2007). Indacaterol, a novel inhaled {beta}2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 29: 871878.
  • Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W et al. (2006). Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 20: 740749.
  • Bradford MM (1976). A rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem 72: 248254.
  • Brookman LJ, Knowles LJ, Barbier M, Elharrar B, Fuhr R, Pascoe S (2007). Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin 23: 31133122.
  • Carter CM, Leighton-Davies JR, Charlton SJ (2007). Miniaturized receptor binding assays: complications arising from ligand depletion. J Biomol Screen 12: 255266.
  • Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R et al. (2011). Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther 337: 600609.
  • Charlton SJ (2009). Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol 158: 165168. Review.
  • Cheng Y, Prusoff WH (1973). Relationship between inhibition constant (K1) and concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic-reaction. Biochem Pharmacol 22: 30993108.
  • Chuchalin AG, Tsoi AN, Richter K, Krug N, Dahl R, Luursema PB et al. (2007). Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 101: 20652075.
  • Coleman RA (2009). On the mechanism of the persistent action of salmeterol: what is the current position? Br J Pharmacol 158: 180182.
  • Contreras ML, Wolfe BB, Molinoff PB (1986). Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors. J Pharmacol Exp Ther 239: 136143.
  • Copeland RA, Pompliano DL, Meek TD (2006). Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730739.
  • De Blasi A, Fratelli M, Marasco O (1988). Certain beta-blockers can decrease beta-adrenergic receptor number: I. Acute reduction in receptor number by tertatolol and bopindolol. Circ Res 63: 273278.
  • Devanathan S, Yao Z, Salamon Z, Kobilka B, Tollin G (2004). Plasmon-waveguide resonance studies of ligand binding to the human beta 2-adrenergic receptor. Biochemistry 43: 32803288.
  • Deyrup MD, Nowicki ST, Richards NG, Otero DH, Harrison JK, Baker SP (1999). Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the beta2-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol 359: 168177.
  • Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R (1999). Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64: 457464.
  • Doggrell SA (1990). The effects of (+/−)-, (+)- and (−)-celiprolol and bromoacetylalprenololmentane at the beta-adrenoceptors of rat isolated cardiovascular preparations. J Pharm Pharmacol 42: 319324.
  • Dowling MR, Charlton SJ (2006). Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M-3 receptor. Br J Pharmacol 148: 927937.
  • Johnson M (1992). Salmeterol: a novel drug for the treatment of asthma. In: Anderson GP, Morley J (eds). New Drugs for Asthma. Birkhauser Verlag: Basel, pp. 7995.
  • Kanniess F, Cameron R, Owen R, Higgins M (2006). Indacaterol, a novel once-daily beta(2)-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with persistent. J Allergy Clin Immunol 117: S196S197.
  • Keith RA, Hwang TF, Murthy VS, Kau ST, Salama AI, Giles RE (1989). ICI 147,798: a slowly dissociable beta adrenoceptor antagonist that causes insurmountable beta-1 and surmountable beta-2 adrenoceptor antagonism in isolated tissues. J Pharmacol Exp Ther 248: 240248.
  • Le Fur G, Paillard JJ, Rougeot C, Uzan A (1980). Tissue levels and displacement of in vivo labelled beta-adrenergic receptors by FM 24, an irreversible or slowly dissociable beta-blocker. Eur J Pharmacol 67: 413418.
  • Lemoine H (1992). Beta-adrenoceptor ligands – characterization and quantification of drug effects. Quant Struct-Act Rel 11: 211218.
  • Lucas M, Homburger V, Dolphin A, Bockaert J (1979). In vitro and in vivo kinetic analysis of the interaction of a norbornyl derivative of propranolol with beta-adrenergic receptors of brain and C6 glioma cells; an irreversible or slowly reversible ligand. Mol Pharmacol 15: 588597.
  • Motulsky HJ, Mahan LC (1984). The kinetics of competitive radioligand binding predicted by the law of mass-action. Mol Pharmacol 25: 19.
  • Mueller H, Motulsky HJ, Sklar LA (1988). The potency and kinetics of the beta-adrenergic receptors on human-neutrophils. Mol Pharmacol 34: 347353.
  • van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP (1996). Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 9: 16841688.
  • van Noord JA, Smeets JJ, Maesen FP (1998). A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction. Respir Med 92: 13461351.
  • Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J (1997). Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 10: 24842489.
  • Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE (1988). The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol 34: 843851.
  • Procopiou PA, Barrett VJ, Bevan NJ, Biggadike K, Butchers PR, Coe DM et al. (2009). Synthesis and structure activity relationships of long-acting β2 adrenergic receptor agonists incorporating arylsulfonamide groups. J Med Chem 53: 22802288.
  • Rosethorne EM, Turner RJ, Fairhurst RA, Charlton SJ (2010). Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 382: 255263.
  • Smith DA, Jones BC, Walker DK (1996). Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16: 243266.
  • Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, Trevethick M (2008). A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. J Pharmacol Toxicol Methods 58: 189197.
  • Sutherland ER, Brazinsky S, Feldman G, McGinty J, Tomlinson L, Denis-Mize K (2009). Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI. Curr Med Res Opin 25: 653661.
  • Sykes DA, Dowling MR, Charlton SJ (2009). Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76: 543551.
  • Szczuka A, Wennerberg M, Packeu A, Vauquelin G (2009). Molecular mechanisms for the presistent bronchiodilatory effect of the β2-adrenoceptor agonist salmeterol. Br J Pharmacol 158: 183194.
  • Tashkin DP, Fabbri LM (2010). Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 11: 149.
  • Teschemacher A, Lemoine H (1999). Kinetic analysis of drug-receptor interactions of long-acting beta(2), sympathomimetics in isolated receptor membranes: Evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J Pharmacol Exp Ther 288: 10841092.
  • Vauquelin G, Charlton SJ (2010). Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161: 488508.
  • Voss HP, Donnell D, Bast A (1992). Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol 227: 403409.
  • Wegener T, Hedenström H, Melander B (1992). Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 102: 535538.
  • Weiland GA, Molinoff PB (1981). Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci 27: 313330.